Abstract:BACKGROUND:Despite the strong association between drug resistance and genetic mutations, the value of molecular diagnosis of drug resistance to guide the treatment of multidrug-resistant tuberculosis (MDR-TB) remains unclear. This is particularly relevant in resource-limited areas, in which it is difficult to implement the drug susceptibility test. Here, we focused on the association of drug susceptibility phenotype and genotype with treatment outcomes in patients with MDR-TB.METHODS:In a prospective cohort study, we enrolled 252 consecutive patients with confirmed MDR-TB between 2010 and 2013, and outcomes were followed-up over the 24-month treatment course in terms of clinical manifestation and sputum conversion. All the isolates were tested for phenotypic susceptibility to second-line drugs in the Mycobacteria Growth Indicator Tube based system, and genotypic mutations were assessed by DNA sequencing.RESULTS:Among the 252 MDR-TB isolates, 88 (34.9%) were resistant to fluoroquinolones and/or second-line injectable drugs, of which 65 (73.9%) harbored a mutation in drug resistance-related genes (gyrA, rrs and eis). In addition, 85 individuals (33.7%) were also resistant to pyrazinamide, with 87.1% containing the pncA mutation. Of 252 MDR-TB patients, 207 (82.1%) had known outcomes and 45 (17.9%) were lost to follow-up. Among those with known outcomes, treatment succeeded in 85.8% with plain MDR-TB, 69.7% with initial resistance to either a fluoroquinolone or second-line injective drugs, 37.5% with initial resistance to pyrazinamide, 29.3% with initial extensively drug resistance. In contrast, among those with known outcomes, treatment success and culture conversion depends on the susceptibility to drug especially for pyrazinamide and fluoroquinolones. In multivariate analysis, pyrazinamide resistance and its related pncA gene mutation were independently associated with a lower risk of culture conversion on at 8weeks and treatment success, while fluoroquinolone resistance was negatively correlated with treatment success. Besides, specific treatment, patient and program variables were also associated with treatment outcome.CONCLUSION:Drug susceptibility testing for pyrazinamide and fluoroquinolones together with genetic information appears to provide a clinically useful indicator of the treatment outcome of MDR-TB in China.

Pnca Mutations Are Associated with Slower Sputum Conversion During Standard Treatment of Multidrug-Resistant Tuberculosis.

Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

Pyrazinamide Resistance and Pnca Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China

Pyrazinamide Resistance among Multidrug-Resistant Tuberculosis Clinical Isolates in a National Referral Center of China and Its Correlations with Pnca, Rpsa, and Pand Gene Mutations

Phenotypic and Genotypic Characterization of Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium Tuberculosis Clinical Isolates in Hangzhou, China.

Emergence and genetic characteristics of pyrazinamide resistant

The Pnca Gene Mutations of Mycobacterium Tuberculosis in Multidrug-Resistant Tuberculosis

Comparative Utility of Genetic Determinants of Drug Resistance and Phenotypic Drug Susceptibility Profiling in Predicting Clinical Outcomes in Patients with Multidrug-Resistant Mycobacterium Tuberculosis

Molecular characteristics of pyrazinamide resistance in Mycobacterium tuberculosis strains

Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China

Selection of Mutations to Detect Multidrug-Resistant Mycobacterium Tuberculosis Strains in Shanghai, China

Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.

Introducing Molecular Testing of Pyrazinamide Susceptibility Improves Multidrug-Resistant Tuberculosis Treatment Outcomes: a Prospective Cohort Study.

‘ZS-MDR-TB' Versus ‘ZR-MDR-TB': Improving Treatment of MDR-TB by Identifying Pyrazinamide Susceptibility

[The Effects of Gene Mutation Related to Drug Resistance and Drug Efflux Pump in Extensively Drug-Resistant Tuberculosis Clinical Isolates].

Improved Treatment Outcome of Multidrug-Resistant Tuberculosis with the Use of a Rapid Molecular Test to Detect Drug Resistance in China.

The mutational signatures of poor treatment outcomes on the drug-susceptible Mycobacterium tuberculosis genome

Genomic Analysis Identifies Mutations Concerning Drug-Resistance and Beijing Genotype in Multidrug-Resistant Mycobacterium Tuberculosis Isolated from China

Genetic factors associated with acquired phenotypic drug resistance and its compensatory evolution during tuberculosis treatment